Sarepta Therapeutics (NASDAQ:SRPT) Cut to Sell at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) was downgraded by HC Wainwright from a "neutral" rating to a "sell" rating in a research report issued on Monday, Marketbeat Ratings reports.

Several other equities research analysts have also recently weighed in on the company. Evercore ISI cut Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price target on the stock. in a research report on Thursday, May 8th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. Oppenheimer decreased their price objective on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Morgan Stanley reduced their target price on Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Finally, UBS Group cut their price target on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $112.22.

Sarepta Therapeutics Stock Down 45.4%

SRPT stock traded down $16.43 during mid-day trading on Monday, reaching $19.75. The company had a trading volume of 30,189,583 shares, compared to its average volume of 1,926,061. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of 15.80 and a beta of 0.61. The stock has a 50 day simple moving average of $46.25 and a two-hundred day simple moving average of $86.03. Sarepta Therapeutics has a 52 week low of $18.33 and a 52 week high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same quarter in the prior year, the business posted $0.73 earnings per share. Sarepta Therapeutics's revenue for the quarter was up 80.2% compared to the same quarter last year. As a group, equities analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Capital International Investors increased its stake in shares of Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares during the last quarter. Norges Bank acquired a new position in Sarepta Therapeutics during the fourth quarter worth $126,315,000. Assenagon Asset Management S.A. increased its position in shares of Sarepta Therapeutics by 438.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock worth $45,477,000 after purchasing an additional 580,123 shares during the last quarter. Wellington Management Group LLP grew its holdings in Sarepta Therapeutics by 27.9% during the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock worth $168,907,000 after purchasing an additional 577,848 shares during the period. Finally, EcoR1 Capital LLC raised its position in shares of Sarepta Therapeutics by 67.8% in the first quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company's stock valued at $82,480,000 after purchasing an additional 522,386 shares during the period. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.